What is Phio Pharmaceuticals Corp?
, a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 9.21M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.